The loss came in narrower than expected, but the number that matters for a $665 million clinical-stage biotech is $208.6 million in cash and securities against roughly $22 million of quarterly operating spend. Management says a registrational plan update for its lead Friedreich ataxia program lands this quarter, with 12-week RESTORE-FA data due in early 2027.
Latest Activity
DSGN Coverage
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch
An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech sitting on pivotal pipeline data have all landed on analysts' radars this week for very…
Here Are Thursday’s Top Wall Street Analyst Research Calls: AON, Apollo Global, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA, and More
Pre-Market Stock Futures: The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA | NVDA Price Prediction) blew out its fiscal third-quarter results and offered strong forward guidance, though perhaps not as…